Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2 / CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin ( HY-14397 )-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Viral Infection | Products > Disease Areas > Depression | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Rheumatoid Arthritis | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Metabolic Disease | Products > Signaling Pathways > TNF Receptor | Products > Signaling Pathways > Chloride Channel | Products > Signaling Pathways > CFTR | Products > Signaling Pathways > Glutathione Peroxidase | Products > Signaling Pathways > NO Synthase
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.